NEW YORK, Feb. 7 /PRNewswire-FirstCall/ -- In response to media inquiries ahead of the company’s February 10 meeting with financial analysts, Pfizer Inc said today it will be exploring strategic alternatives for Pfizer Consumer Healthcare (PCH). These alternatives include retaining, spinning off or selling the business.
The objective of the review is to unlock the value of the business for Pfizer shareholders at a time when market valuations are attractive for large, high-quality consumer businesses. PCH is a leading global consumer healthcare business with a portfolio of well-known, growing brands.
Pfizer said that the welfare of PCH colleagues and other Pfizer colleagues supporting the business will remain a high priority throughout the process, consistent with our long-standing values and respect for colleagues throughout the company.
At the February 10 meeting, Pfizer will provide a comprehensive overview of its business and financial strategy, including key products and its industry-leading pipeline, as well as further elaborate on this strategic initiative.
Source: Pfizer Inc
